Clinical Trial: Mesalazine for Irritable Bowel Syndrome with Diarrhea (IBS-D), United Kingdom
The Nottingham University Hospitals Trust, King’s Mill Hospital Mansfield, Derby Royal Hospital and Wythenshawe Hospital Manchester are looking for men and women age 18-75 with Rome III criteria diarrhea-predominant IBS to participate in a clinical trial of the medication mesalazine for the treatment of IBS. Other eligibility requirements or exclusions may apply. Mesalazine is a common, established treatment for inflammatory bowel disease (IBD). Because of recent research showing that chronic, low-level gut inflammation may be a factor in irritable bowel syndrome, the researchers hypothesize that mesalazine may be an effective treatment for IBS as well.
The study involves 4 hospital visits of 1-2 hours each over the course of 14 weeks. Participants will receive either a placebo or mesalazine in a double-blind protocol, meaning neither the volunteers nor the doctor or nurse will be aware of whether specific individuals are given mesalazine or a placebo.
Volunteers who complete the study will be paid 150 pounds as compensation for expenses or time off from employment.
For further information, contact Dr Ching Lam (Clinical Research Fellow) at email@example.com or 01159249924 ext 7061.
IBS Impact has summarized this information from a posting on the website of the IBS Network, the national charity for irritable bowel syndrome in the U.K. and this study’s current listing at ClinicalTrials.gov, a worldwide database that is administered by the United States National Institutes of Health.